McKesson Corporation reported fiscal third‑quarter 2026 results that surpassed expectations, with revenue of $106.2 billion—an 11% year‑over‑year increase—and adjusted earnings per share of $9.34, beating the consensus estimate of $9.16 by $0.18 per share. The company also lifted its full‑year adjusted EPS guidance to a range of $38.80 to $39.20, up from the prior guidance of $38.20 to $38.60, signaling confidence in continued momentum across its core distribution businesses.
Comparing the quarter to the same period a year earlier, McKesson’s revenue grew from $95.3 billion in Q3 2025 to $106.2 billion, a 12% increase, while diluted EPS rose from $8.03 to $9.34, a 16% jump. Against the preceding quarter, revenue was up 4.5% from $101.8 billion in Q2 2026, and EPS increased from $8.78 to $9.34, reflecting a steady acceleration in profitability.
Segment analysis shows that the North American Pharmaceutical division drove the bulk of the revenue growth, with a 9% increase to $45.1 billion, propelled by higher prescription volumes and a 26% year‑over‑year rise in GLP‑1 distribution revenues that reached $14 billion. The Oncology & Multispecialty segment posted a 29% revenue gain to $12.3 billion, while the Biopharma Services platform grew 15% to $8.7 billion, underscoring the company’s strategic focus on high‑margin specialty markets.
Operating margin expanded to 9.9% from 9.4% in the prior year, driven by improved cost discipline and a favorable mix shift toward higher‑margin specialty products. The company’s investment in automation and AI‑enabled logistics has reduced per‑unit handling costs, while the acquisition of Prism Vision and Core Ventures has added new revenue streams and synergies that support margin growth.
CEO Brian Tyler highlighted the company’s “strong momentum across oncology, biopharma services, and North American distribution” and emphasized that technology and automation are “streamlining operations and elevating the customer experience.” CFO Britt Vitalone noted that record quarterly revenue and adjusted operating profits were “supported by year‑over‑year double‑digit growth in our oncology and multispecialty and biopharma services platforms.”
Despite the earnings beat and guidance raise, McKesson’s stock slipped 0.74% in aftermarket trading on February 4. Analysts cited valuation concerns and the company’s ongoing separation of its medical‑surgical business as factors that tempered enthusiasm, even as the results underscored robust demand in high‑growth specialty segments.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.